Sera Prognostics Raises $36 Million Series D Financing

Blue Ox Healthcare Partners Led the Investment Round Alongside Two Strategic Healthcare Companies.

Friday, November 27, 2020

Proceeds from the Series D financing will be used to increase the commercialization of Sera’s PreTRM® test and to measure real-world clinical improvements and economic savings in collaboration with top health plans and providers.

Sera’s products focus on the early prediction of a woman’s individualized risk of preterm birth and other pregnancy complications. The Company’s PreTRM® test is the only clinically-validated, commercially available biomarker blood test to accurately assess a woman’s individualized risk of premature delivery. The PreTRM® test enables earlier, more proactive clinical decisions designed to prolong gestation, improve the health of the baby and lower healthcare costs. As evidenced by a key scientific publication recently released online in Obstetrics & Gynecology (December 2019; volume 134, issue 6), Sera is the leading authority in biomarker preterm birth risk prediction.

“Preterm birth – the leading cause of infant mortality – is an unaddressed global crisis, accounting for over $30 billion in excess annual spending in the U.S. alone. Blue Ox’s investment in Sera is a testament to the industry’s confidence in PreTRM® and Sera’s mission of improving the health of pregnant women and newborns while reducing the cost of treatments for premature birth,” said Gregory C. Critchfield, MD, MS, Chairman and Chief Executive Officer of Sera. “We are thrilled to have innovative healthcare investor Blue Ox, a major U.S. healthcare company, and an international diagnostics manufacturer join our strong investor syndicate, and look forward to leveraging their combined strategic, financial, operational and healthcare industry expertise as we commercialize personalized medicine innovations in pregnancy care and scale our business.”

“Sera’s leading-edge platform reflects healthcare’s move towards individualized, value-based care and underscores Blue Ox’s commitment to supporting companies targeting this transformation and poised for tremendous growth. Sera’s PreTRM® test is revolutionizing pregnancy care by accurately identifying a woman’s individualized risk for preterm birth and supporting better outcomes at lower costs,” added Charles D. Kennedy, MD, Managing Partner at Blue Ox. “Importantly, PreTRM® is the only commercially available blood test that arms practitioners with critical risk information they need to identify and treat patients at elevated risk of premature delivery using proactive interventions and guideline-based therapies. As a result, we believe PreTRM® will be the go-to solution for commercial plans, Medicaid programs, employers and risk-based providers seeking to effectively manage the clinical and economic epidemic of preterm birth. We are pleased to support Sera at this pivotal point in its evolution.”

Existing investors Domain Associates, InterWest Partners, Laboratory Corporation of America Holdings, Catalyst Health Ventures, and Chione Ltd also participated in the Series D investment round.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.